Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7221319 | 0.85 | GHSR (0.39) | CA1CA2CA7CA9TSHR | |
| SCHEMBL7246157 | 0.84 | FOLH1 (0.39) | CA1CA2CA7CA9PPARA | |
| SCHEMBL15524705 | 0.82 | CA1 (0.42) | CA1CA2CA7CA9TSHR | |
| SCHEMBL15524706 | 0.82 | CA1 (0.42) | CA1CA2CA7CA9TSHR | |
| SCHEMBL4570494 | 0.82 | CA1 (0.42) | CA1CA2CA7CA9TSHR | |
| SCHEMBL16820724 | 0.81 | CA1 (0.41) | CA1CA2CA7CA9TSHR | |
| SCHEMBL18027565 | 0.81 | CA1 (0.41) | CA1CA2CA7CA9TSHR | |
| SCHEMBL16616685 | 0.81 | CA1 (0.41) | CA1CA2CA7CA9TSHR | |
| SCHEMBL7221734 | 0.81 | PLA2G10 (0.34) | CA1CA2CA7CA9PPARA | |
| SCHEMBL519636 | 0.79 | L3MBTL1 (0.44) | TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6512003-B2 | Depolymerization activity and polymerization inhibition of tubulin; antiproliferative agents | PARKER HUGHES INSTITUTE | 2003-01-28 | — | — | US | disclosed |
| US-20020151580-A1 | Synthetic spiroketal pyranes as potent anti-cancer agents and use | PARKER HUGHES INSTITUTE (US) | 2002-10-17 | — | — | US | disclosed |
| US-6335364-B1 | TUBULIN POLYMERIZATION INHIBITORS; ANTIPROLIFERATIVE AND ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2002-01-01 | — | — | US | disclosed |
| EP-1091978-A2 | SYNTHETIC SPIROKETAL PYRANES AS POTENT ANTI-CANCER AGENTS | Parker Hughes Institute (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000000514-A9 | SYNTHETIC SPIROKETAL PYRANES AS POTENT ANTI-CANCER AGENTS | PARKER HUGHES INST (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000000514-A2 | SYNTHETIC SPIROKETAL PYRANES AS POTENT ANTI-CANCER AGENTS | PARKER HUGHES INSTITUTE (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151580-A1 | Synthetic spiroketal pyranes as potent anti-cancer agents and use | TUBB6, TUBAL3, TUBB1 | CA1 3104/4885CA2 3849/4885CA7 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.